COMMON STOCK PURCHASE WARRANT Applied Therapeutics, Inc.Common Stock Purchase Warrant • June 27th, 2022 • Applied Therapeutics Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Issue Date”) and on or prior to 5:00 p.m. (New York City time) on June 27, 2027, (the “Termination Date”) but not thereafter, to subscribe for and purchase from Applied Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock, $0.0001 par value per share, of the Company (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Applied Therapeutics, Inc. 3,000,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • February 17th, 2021 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
Applied Therapeutics, Inc. Up to $100,000,000 of Common Stock ($0.0001 par value) Equity Distribution AgreementEquity Distribution Agreement • January 26th, 2022 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
INDEMNITY AGREEMENTIndemnification Agreement • April 24th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between APPLIED THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement terminates any and all previous indemnification agreements entered into by and between the Company and the Indemnitee.
Applied Therapeutics, Inc. 20,000,000 Shares of Common Stock ($0.0001 par value) and Pre-Funded Warrants to purchase 10,000,000 Shares of Common Stock and Warrants to purchase 30,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 27th, 2022 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 29th, 2024 • Applied Therapeutics Inc. • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 27, 2024, by and among Applied Therapeutics, Inc., a Delaware corporation, with principal office located at 545 Fifth Avenue, Suite 1400, New York, New York 10017 (the "Company") and the undersigned buyers, (each, a "Buyer" and, collectively, the "Buyers").
APPLIED THERAPEUTICS INC.Employment Agreement • March 13th, 2020 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
This letter agreement (the “Agreement”) sets forth the terms and conditions of your continued full time employment with Applied Therapeutics Inc. (the “Company”), effective as of March 9, 2020 (the “Effective Date”).
ContractWarrant Agreement • April 12th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE. NO SUCH DISTRIBUTION OR RESALE MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT OR QUALIFICATION RELATED THERETO OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS.
Underwriting AgreementUnderwriting Agreement • April 29th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 24th, 2023 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of April 23, 2023, by and among Applied Therapeutics, Inc., a Delaware corporation, with headquarters located at 545 Fifth Avenue, Suite 1400, New York, NY 10017 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").
APPLIED THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT November 5, 2018Investors’ Rights Agreement • April 12th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 5th day of November, 2018, by and among Applied Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof, and Shoshana Shendelman (the “Founder”).
Applied Therapeutics, Inc. Up to $75,000,000 of Common Stock ($0.0001 par value) Sales AgreementSales Agreement • August 11th, 2023 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 12th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AGREEMENT (this, “Agreement”), dated October 26, 2016 (the “Effective Date”), is by and between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York corporation (“Columbia”), and APPLIED THERAPEUTICS, INC., a Delaware corporation (“Company”).
APPLIED THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • April 12th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations
May 28, 2019 Les Funtleyder Re: Separation Agreement Dear Les:Separation Agreement • August 12th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
This letter sets forth the substance of the separation agreement (the “Agreement”) which Applied Therapeutics Inc. (the “Company”) is offering to you to aid in your employment transition.
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT AND A RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT, AS AMENDED FROM TIME TO TIME, AMONG CERTAIN...Warrant Agreement • April 12th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • Delaware
Applied Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that , or his registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) , 2028 up to shares of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $ per share. The shares purchasable upon exercise of this Common Stock Purchase Warrant (“Warrant”), and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively. The Common Stock shall have the rights, restrictions and privileges set forth in the certificate of incorporation of the Company, as amended or restated from time to time (the “Certificate of Incorporatio
CONFIDENTIALSeparation Agreement • April 15th, 2024 • Applied Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation of employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to together as the “Parties” and each as a “Party.”
APPLIED THERAPEUTICS INC. LETTER AMENDMENT TO OFFER LETTEROffer Letter • December 20th, 2024 • Applied Therapeutics, Inc. • Pharmaceutical preparations
This letter amendment (this “Letter Amendment”) modifies certain provisions set forth in that certain Offer Letter by and between Applied Therapeutics Inc. (the “Company”) and you, dated as of November 17, 2023 (the “Offer Letter”) in connection with your appointment as interim Chief Executive Officer of the Company. Capitalized terms used but not otherwise defined in this Letter Amendment shall have the meanings given to them in the Offer Letter.
EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between APPLIED THERAPEUTICS, INC. and MERCURY PHARMA GROUP LIMITED January 3, 2023Exclusive License and Supply Agreement • March 23rd, 2023 • Applied Therapeutics Inc. • Pharmaceutical preparations • England and Wales
This Exclusive License and Supply Agreement (this “Agreement”) dated as of January 3, 2023 is made by and between Applied Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware in the U.S. with its head office at 545 5th Ave Suite 1400, New York, NY 10017 (“Applied”), and Mercury Pharma Group Limited (trading as Advanz Pharma Holdings), a company organized and existing under the laws of England and Wales with its head office at Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom and registered under number 02330913 (“Advanz”) (each, a “Party” and collectively, the “Parties”).
Re: Warrant Exchange AgreementWarrant Exchange Agreement • October 13th, 2023 • Applied Therapeutics Inc. • Pharmaceutical preparations
This letter agreement (the “Agreement”) confirms the agreement of Applied Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to which the Stockholders have agreed to exchange an aggregate of 5,658,034 shares (the “Shares”) of Common Stock, par value $0.0001 per share (the “Common Stock”), beneficially owned by the Stockholders in consideration for one or more Common Stock purchase warrants in the form attached hereto as Exhibit A (each a “Warrant”) to purchase an aggregate of 5,658,034 shares of Common Stock (the “Warrant Shares”) on the terms specified below.
CONFIDENTIALSeparation Agreement • December 20th, 2024 • Applied Therapeutics, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation of employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to together as the “Parties” and each as a “Party.”
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 13th, 2020 • Applied Therapeutics Inc. • Pharmaceutical preparations
This Amendment to Employment Agreement (this “Amendment”) is entered into on March 9, 2020, by and between Riccardo Perfetti (“Executive”) and Applied Therapeutics Inc., a Delaware corporation (the “Company”). For purposes of this Amendment, Executive and the Company may collectively be referred to as “the Parties.”
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT AND A RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT, AS AMENDED FROM TIME TO TIME, AMONG CERTAIN...Common Stock Purchase Warrant • January 25th, 2019 • Applied Therapeutics Inc. • Pharmaceutical preparations • Delaware
Applied Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that , or his registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) , 2028 up to shares of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $ per share. The shares purchasable upon exercise of this Common Stock Purchase Warrant (“Warrant”), and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively. The Common Stock shall have the rights, restrictions and privileges set forth in the certificate of incorporation of the Company, as amended or restated from time to time (the “Certificate of Incorporatio
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 29th, 2024 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of February 27, 2024, by and among Applied Therapeutics, Inc., a Delaware corporation, with headquarters located at 545 Fifth Avenue, Suite 1400, New York, NY 10017 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").
AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT NUMBER ____ Applied Therapeutics, Inc.Common Stock Purchase Warrant • May 11th, 2023 • Applied Therapeutics Inc. • Pharmaceutical preparations
Reference is made to the above captioned Common Stock Purchase Warrant (the “Original Warrant”) that entitles the holder thereof and identified in the signatures pages hereto (the “Holder”), upon the terms and subject to the limitations on exercise and the conditions set forth in therein, at any time on or after the Issue Date and on or prior to the Termination Date but not thereafter, to subscribe for and purchase from Applied Therapeutics, Inc., a Delaware corporation (the “Company”), the Warrant Shares specified therein.
